Milestone Pharmaceuticals (MIST) announced that cardamyst nasal spray, its first commercial product, is now available through U.S. retail pharmacies. Cardamyst is a prescription medication indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults. Implementation of a rapid commercialization plan is underway with a national sales force to be deployed in mid-February 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals Secures $75M Non-Dilutive Royalty Financing
- Milestone Pharmaceuticals: Undervalued CARDAMYST Opportunity with EU Upside and Strong Risk‑Reward Supporting Buy Rating
- Milestone’s PSVT nasal spray MAA accepted by EMA
- Milestone announces acceptance of MAA by EMA for etripamil nasal spray
- Milestone Pharmaceuticals price target raised to $8 from $4 at Wells Fargo